Skip to content

Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia

Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia

Status
Enrolling by invitation
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06743243
Enrollment
174
Registered
2024-12-19
Start date
2025-07-23
Completion date
2026-12-30
Last updated
2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anesthesia

Keywords

K-CAB, K-CAB OD tab., P-CAB, Famotidine, Tegoprazan, general anesthesia

Brief summary

The aim of this study is to compare gastric pH right after endotracheal intubation for general anesthesia in patients pretreated with tegoprazan, famotidine, or placebo.

Detailed description

This clinical trial is a prospective, randomized, double-blind, multicenter, investigator-initiated trial that aims to demonstrate the preventive effect of tegoprazan on preoperative aspiration in patients scheduled to undergo surgery using general anesthesia. Subjects who meet the inclusion/exclusion criteria will be randomly assigned to the tegoprazan administration group (Group T), famotidine administration group (Group F), or placebo administration group (Group C) in the same ratio of 1:1:1.

Interventions

Tegoprazan OD tab. 50 mg PO + Saline 20ml IV, one hour before general anesthesia.

DRUGFamotidine

Famotidine 20mg/10ml+saline 10ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.

DRUGPlacebo

Tegoprazan OD tab. 50 mg placebo PO + Saline 20ml IV, one hour before general anesthesia.

Sponsors

Korea University Guro Hospital
CollaboratorOTHER
HK inno.N Corporation
CollaboratorINDUSTRY
Eunpyeong St. Mary's Hospital, The Catholic University of Korea
CollaboratorUNKNOWN
Asan Medical Center
CollaboratorOTHER
Seok Kyeong Oh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

1. Has a plan to undergo surgery with general anesthesia with inhalation or total Intravenous 2. Subjects aged between 20 and 69 years 3. ASA classification I - III

Exclusion criteria

1. Conduct Emergency surgery 2. BMI(Body Mass Index) ≥ 35 3. Has a history of drug abuse or depandency. 4. Has a history of Anesthetic allergy 5. Has a plan to undergo resection(gastric cancer, esophageal cancer)

Design outcomes

Primary

MeasureTime frame
Gastric pH right after endotracheal intubationright after endotracheal intubation

Secondary

MeasureTime frame
Change of oral, esophageal and gastric pHoral pH(before anesthesia, endotracheal intubation 30 minutes after surgery started, right after surgery end, extubation, 30minutes after enter the postanesthesia care unit), esophageal and gastric pH(right after intubation)
Gastric volume evaluated by Ultrasoundbefore anesthesia, right after end of surgery, 30 minutes after enter the postanesthesia care unit
Risk of aspiration(pH < 2.5, Gastric volume > 0.4mL/kg) and frequency of complications(aspiration etc.)before anesthesia, right after intubation, 30 minutes after surgery started, right after surgery end, extubation, 30 minutes after enter the postanesthesia care unit

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026